Clinical Trials Directory

Trials / Completed

CompletedNCT00054795

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Randomized Phase III Trial of Xcytrin® (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer Undergoing Whole Brain Radiation Therapy

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
550 (planned)
Sponsor
Pharmacyclics LLC. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary purpose of the study is to determine if patients with brain metastases from non-small cell lung cancer treated with Motexafin Gadolinium and whole brain radiation therapy retain their neurologic function and ability to think for a longer time compared to patients treated with whole brain radiation therapy alone.

Conditions

Interventions

TypeNameDescription
DRUGMotexafin Gadolinium

Timeline

First posted
2003-02-13
Last updated
2007-05-08

Locations

92 sites across 8 countries: United States, Australia, Austria, Belgium, Canada, France, Germany, Netherlands

Source: ClinicalTrials.gov record NCT00054795. Inclusion in this directory is not an endorsement.

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART) (NCT00054795) · Clinical Trials Directory